Precision’s itinerant Car-T cells go on another journey
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
Fresh antitrust push hits biopharma
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
Agios strengthens the case for mitapivat
A filing in pyruvate kinase deficiency beckons, but bigger indications could be trickier.
Astrazeneca shows megamergers were still possible in 2020
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Agios gets $1.8bn and a new focus
Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
Small Galapagos setback prompts a bigger loss of sentiment
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
